CV division

[anonymous]

How much longer until they pull the cord? Pfizer had a small downsizing

 

[anonymous]

PFE has a smaller ... unit.

 

[anonymous]

PFE has a smaller ... unit.

”That’s what she said!”

 

[anonymous]

They could get rid of reps at anytime. Eliquis has no competition

 

[anonymous]

They could get rid of reps at anytime. Eliquis has no competition

Eliquis will be promoted until very close to the market entry of its generic. Despite upcoming pricing headwinds there is more business to be had. There will be increasing intrusion of generic Pradaxa which is happening now and by Q2 2027 generic Xarelto will be a factor.
Afib prevalence is expanding. Every bit that can captured is big revenue.

 

[anonymous]

How much longer until they pull the cord? Pfizer had a small downsizing

Downsizing was of a few hospital reps. There’s less than 100 of them nationwide.

 

[anonymous]

And there are 500 BMS CV reps!

 

[anonymous]

Guessing after Q4 earnings come out with be a good predictor.

 

[anonymous]

Eliquis will be promoted until very close to the market entry of its generic. Despite upcoming pricing headwinds there is more business to be had. There will be increasing intrusion of generic Pradaxa which is happening now and by Q2 2027 generic Xarelto will be a factor.
Afib prevalence is expanding. Every bit that can captured is big revenue.

Ex Xarelto rep here. We all thought we had at least two more years before Armageddon. Not true! And they do not care! Credo=Lies!!

 

[anonymous]

Ex Xarelto rep here. We all thought we had at least two more years before Armageddon. Not true! And they do not care! Credo=Lies!!

The difference is that Xarelto has been a sinking ship for quite some time. No growth, market share deflated.

While it was certainly a surprise to see the plug pulled on Xarelto promotion so far in advance of LOE, there was no attainable path to creating additional revenue in the VTE and Afib. Eliquis owns the space.

 

[anonymous]

RBD said BMS place to be. Not with leaving for 20k more the grass isn’t greener! This was said during end of year call. It was laughable a lot of good cv people are leaving. Cytokinetics are reaching out to reps.

 

[anonymous]

The difference is that Xarelto has been a sinking ship for quite some time. No growth, market share deflated.

While it was certainly a surprise to see the plug pulled on Xarelto promotion so far in advance of LOE, there was no attainable path to creating additional revenue in the VTE and Afib. Eliquis owns the space.

Exactly why the layoffs are coming….

 

[anonymous]

Exactly why the layoffs are coming….

Is there any division that won’t be cut? Does any leader have any clue what you are doing?

 

[anonymous]

No transparency, carpet could get pulled at anytime.

 

[anonymous]

Yea I guess 20k is nothing, over 10 years it’s 200k.

 

[anonymous]

Yea I guess 20k is nothing, over 10 years it’s 200k.

Literally said 20k is nothing and not worth leaving for!!

 

[anonymous]

Literally said 20k is nothing and not worth leaving for!!

Well can we have a little bit of certainly we will have a job in a month around here? We hear rumors every week and frankly it is getting hard to concentrate on staying

 

[anonymous]

Well can we have a little bit of certainly we will have a job in a month around here? We hear rumors every week and frankly it is getting hard to concentrate on staying

BMS better start a retention plan and fast for current reps Cyto is reaching out to all levels. BMS has outstanding CV reps but they need to be smart about this. I am not sure they have the strategical foresight.

 

[anonymous]

20k is definitely worth leaving for. Money is money. We don’t do this for charity

 

[anonymous]

BMS better start a retention plan and fast for current reps Cyto is reaching out to all levels. BMS has outstanding CV reps but they need to be smart about this. I am not sure they have the strategical foresight.

Strategical…